AgomAb Therapeutics (AGMB) Stock Price, News & Analysis

Company Overview

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company's name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones. The company emphasizes creating antibody formats that mimic or enhance natural ligand-receptor interactions to restore or improve biological signaling. While specific programs and indications evolve with research and regulatory progress, AgomAb’s platform is positioned to address therapeutic areas that may benefit from receptor activation rather than inhibition.

AgomAb conducts its research and development through in-house scientific teams and may pursue strategic partnerships or collaborations to advance lead candidates toward clinical testing and commercialization. Public disclosures such as SEC filings, company press releases and investor presentations are the primary sources for up-to-date information on the company’s pipeline, program timelines, corporate leadership and geographic footprint. Investors and analysts should consult those documents for specific details about AgomAb’s ongoing programs and corporate developments.

Key Stats

• Today's Range: $10.98 to $11.55
• 50-Day Range: $9.85 to $14.31
• 52-Week Range: $9.00 to $17.45
• Volume: 34,113 shs
• Average Volume: 154,107 shs
• Market Capitalization: $416.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.00
• Consensus Rating: Moderate Buy

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Biological Products, Except Diagnostic Substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AGMB
• CIK: 2020932
• Web: N/A
• Phone: (323) 302-3530
• Fax: N/A
• Employees: 62
• Year Founded: 2017

Price Target and Rating

• Average Price Target for AgomAb Therapeutics: $32.00
• High Price Target: $36.00
• Low Price Target: $28.00
• Potential Upside/Downside: +178.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 36,237,000
• Free Float: N/A
• Market Cap: $416.73 million
• Optionable: N/A
• Beta: N/A